BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane.

被引：0
|
作者：
Moreno-Aspitia, A.
Hillman, D. W.
Wiesenfeld, M.
Hobday, T. J.
Rowland, K. M.
Northfelt, D. W.
Tenner, K. S.
Palmieri, F. M.
Perez, E. A.
机构：
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] Mayo Clin, Rochester, MN USA
[3] Oncol Associates, Cedar Rapids, IA USA
[4] Carle Canc Ctr, Urbana, IL USA
[5] Mayo Clin Scottsdale, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22S / 22S
页数：1
相关论文
共 50 条
  • [1] A Phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer
    Bianchi, G.
    Loibl, S.
    Zamagni, C.
    Ardizzoni, A.
    Raab, G.
    Siena, S.
    Wolf, C.
    Westermeier, T.
    Bergamini, L.
    Gianni, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [2] Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Watanabe, J.
    Horiguchi, J.
    Masuda, N.
    Aogi, K.
    Sato, R.
    Tokudome, T.
    Peck, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas
    El-Khoueiry, A. B.
    Rankin, C.
    Lenz, H. J.
    Philip, P.
    Rivkin, S. E.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma.
    O'Dwyer, PJ
    Rosen, M
    Gallagher, M
    Schwartz, B
    Flaherty, KT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 193S - 193S
  • [5] Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane
    Ahn, JH
    Kim, SB
    Kim, TW
    Ahn, SH
    Kim, SM
    Park, JM
    Lee, JS
    Kang, YK
    Kim, WK
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (04) : 547 - 553
  • [6] Efficacy of the CMFVP Regimen in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
    Grenader, Tal
    ONKOLOGIE, 2012, 35 (1-2): : 24 - 26
  • [7] Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer.
    Dahut, W. L.
    Scripture, C. D.
    Posadas, E. M.
    Wu, S.
    Arlen, P. M.
    Gulley, J. L.
    Wright, J.
    Chen, C. C.
    Jones, E.
    Figg, W. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 218S - 218S
  • [8] A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
    Lida Mina
    Ian Krop
    Robin T. Zon
    Steven J. Isakoff
    Charles J. Schneider
    Menggang Yu
    Cindy Johnson
    LaTrice G. Vaughn
    Yanping Wang
    Maria Hristova-Kazmierski
    Oluwatoyin O. Shonukan
    George W. Sledge
    Kathy D. Miller
    Investigational New Drugs, 2009, 27 : 565 - 570
  • [9] A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
    Mina, Lida
    Krop, Ian
    Zon, Robin T.
    Isakoff, Steven J.
    Schneider, Charles J.
    Yu, Menggang
    Johnson, Cindy
    Vaughn, LaTrice G.
    Wang, Yanping
    Hristova-Kazmierski, Maria
    Shonukan, Oluwatoyin O.
    Sledge, George W.
    Miller, Kathy D.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (06) : 565 - 570
  • [10] Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma
    Eisen, T.
    Ahmad, T.
    Marais, R.
    Gibbens, I.
    James, M.
    Affolter, A.
    Chao, D.
    Bergamini, L.
    Schwartz, B.
    Gore, M. E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 349 - 349
12345